Integrative Computational Modeling of Distinct Binding Mechanisms for Broadly Neutralizing Antibodies Targeting SARS-CoV-2 Spike Omicron Variants: Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape.

Publication date: May 22, 2025

In this study, we conducted a comprehensive analysis of the interactions between the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and four neutralizing antibodies-S309, S304, CYFN1006, and VIR-7229. Using integrative computational modeling that combined all-atom molecular dynamics (MD) simulations, mutational scanning, and MM-GBSA binding free energy calculations, we elucidated the structural, energetic, and dynamic determinants of antibody binding. Our findings reveal distinct dynamic binding mechanisms and evolutionary adaptation driving the broad neutralization effect of these antibodies. We show that S309 targets conserved residues near the ACE2 interface, leveraging synergistic van der Waals and electrostatic interactions, while S304 focuses on fewer but sensitive residues, making it more susceptible to escape mutations. The analysis of CYFN-1006. 1 and CYFN-1006. 2 antibody binding highlights broad epitope coverage with critical anchors at T345, K440, and T346, enhancing its efficacy against variants carrying the K356T mutation, which caused escape from S309 binding. Our analysis of broadly potent VIR-7229 antibody binding to XBB. 1.5 and EG. 5 Omicron variants emphasized a large and structurally complex epitope, demonstrating certain adaptability and compensatory effects to F456L and L455S mutations. Mutational profiling identified key residues crucial for antibody binding, including T345, P337, and R346 for S309 as well as T385 and K386 for S304, underscoring their roles as evolutionary “weak spots” that balance viral fitness and immune evasion. The results of the energetic analysis demonstrate a good agreement between the predicted binding hotspots, reveal distinct energetic mechanisms of binding, and highlight the importance of targeting conserved residues and diverse epitopes to counteract viral resistance.

Open Access PDF

Concepts Keywords
Antibody ACE2 protein, human
Cyfn1006 Angiotensin-Converting Enzyme 2
Driving Angiotensin-Converting Enzyme 2
Free Antibodies, Neutralizing
Mutational Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
antibody binding
binding energetics
Broadly Neutralizing Antibodies
Broadly Neutralizing Antibodies
COVID-19
Epitopes
Epitopes
Evolution, Molecular
evolutionary mechanisms
Humans
immune escape
Immune Evasion
molecular dynamics
Molecular Dynamics Simulation
Mutation
mutational scanning
Omicron variants
Protein Binding
protein stability
SARS-CoV-2
SARS-CoV-2 spike protein
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Isoxaflutole
drug DRUGBANK Coenzyme M
disease IDO protein
disease MESH infection
disease MESH SD1
disease IDO host
disease IDO production
drug DRUGBANK Succimer
disease IDO immune response
drug DRUGBANK Pidolic Acid
drug DRUGBANK Water
drug DRUGBANK Flunarizine
disease IDO algorithm
drug DRUGBANK Amber
disease IDO site
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Proline
drug DRUGBANK Serine
disease MESH mutation frequency
disease IDO susceptibility
disease IDO cell
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK (S)-Des-Me-Ampa
disease IDO infectivity
drug DRUGBANK Guanosine
disease MESH SARS CoV 2 Infection
drug DRUGBANK Troleandomycin
drug DRUGBANK Heparin
drug DRUGBANK Ranitidine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *